SCHEDULE 13D/A: Catheter Precision CEO David Jenkins Receives Significant Stock Option Grant, Updates Beneficial Ownership

Catheter Precision, Inc. has filed an amended Schedule 13D revealing an updated beneficial ownership stake for CEO David Jenkins and related entities, alongside a new grant of 450,000 stock options to Mr. Jenkins.

Summary

• David Jenkins, Executive Chairman and CEO of Catheter Precision, Inc., and affiliated entities have updated their beneficial ownership in the company.
• Mr. Jenkins' aggregate beneficial ownership stands at 194,182 shares, representing 2.1% of the common stock, which includes 90,000 shares subject to currently exercisable options.
• FatBoy Capital, L.P., SeaCap Management LLC, and Dalin Class Trust each beneficially own 70,970 shares, representing 0.1% of the common stock class.
• The Linda Jenkins Charitable Remainder Trust beneficially owns 226 shares, representing 0.0% of the common stock class.
• On January 29, 2025, the Compensation Committee granted David Jenkins options to purchase 450,000 shares of common stock at an exercise price of $0.42 per share.
• These options vest over four years: 90,000 shares vested immediately on January 29, 2025, and 120,000 shares vest annually on January 29, 2026, 2027, and 2028.
• The options have a ten-year term, expiring on January 29, 2035, and are intended as Incentive Stock Options under Section 422 of the Internal Revenue Code.
• The grant is in consideration of past services and to incentivize future performance.
• The reporting persons state their acquisitions are for investment purposes and may include additional open market purchases or sales, or estate planning transactions.

Sentiment

Score: 6

Explanation: The document is largely factual, detailing beneficial ownership and a new stock option grant. The grant to the CEO is a positive for incentive alignment, but the document does not contain significant new positive or negative financial performance information. The detailed disclosure of family holdings and blockers adds transparency but doesn't inherently shift sentiment strongly.

Positives

• The grant of 450,000 stock options to CEO David Jenkins at an exercise price of $0.42 per share aligns management's incentives with shareholder value creation, as the options vest over four years, encouraging long-term performance.
• The options are intended to qualify as Incentive Stock Options, which can offer favorable tax treatment to the recipient, potentially increasing the attractiveness of the compensation package.

Negatives

• The beneficial ownership percentages for most reporting entities (FatBoy Capital, SeaCap Management, Dalin Class Trust) are relatively low at 0.1%, and Linda Jenkins Charitable Remainder Trust at 0.0%, which might suggest limited direct financial commitment from these specific entities relative to the overall company.
• The document highlights various beneficial ownership blockers on a significant number of shares (e.g., 873,866 shares from warrants, 817,157 shares of Series X Preferred Stock) held by related parties, which currently prevent their conversion into common stock, limiting their immediate impact on the public float and potentially liquidity.

Risks

• While reporting persons state no present intent to change the company's structure, capitalization, or management, David Jenkins, as a director and executive officer, reserves the right to consider various transactions in the best interests of the Company, including those that could lead to significant corporate changes.
• A substantial number of shares beneficially owned by related parties (e.g., Jenkins Family Charitable Institute, Missiaen Huck, Casey A. Jenkins) are subject to beneficial ownership blockers or are not currently exercisable, which could impact future dilution or control dynamics if these blockers are removed or options/warrants become exercisable.
• The ultimate liability for all tax-related items concerning the stock options remains the Participant's responsibility, and the Company makes no representation or undertaking regarding tax treatment, which could expose the CEO to unexpected tax liabilities.

Future Outlook

The reporting persons intend for their acquisitions to be for investment purposes and may engage in additional open market purchases or sales, or estate planning transactions in the future. David Jenkins, as an executive officer and director, retains control over the Company and may consider various transactions in the Company's best interests, including potential corporate changes, asset sales, or capitalization adjustments, though no present intent for such actions is stated.

Management Comments

• "Options granted to David Jenkins were in consideration of past services and to incentivize future performance."
• "Mr. Jenkins exercises control over the Company to the extent that he is a director and executive officer of the Company, and may consider various transactions that are in the best interests of the Company from time to time, including transactions of the types described above, and the reporting persons and the other persons listed in Item 2 will continue to review their investment in the Company, and reserve the right to change their intentions with respect to any or all of such matters."

Industry Context

This filing is specific to the beneficial ownership and executive compensation structure of Catheter Precision, Inc., a company focused on cardiac electrophysiology medical technologies. It does not provide broader industry trends or competitive analysis, but the grant of significant stock options to the CEO is a common practice in the medical technology sector to align executive incentives with long-term company growth and innovation.

Corporate Governance

Related Party Transactions

• Grant of 450,000 stock options to David Jenkins, the Executive Chairman and CEO of Catheter Precision, Inc.
• Beneficial ownership by Linda Jenkins Charitable Remainder Trust, where Linda Jenkins (David Jenkins' wife) is the trustee.
• Beneficial ownership by Dalin Class Trust, where David Jenkins is the sole trustee.
• Shared voting and dispositive power through Fatboy Capital, L.P., where SeaCap Management LLC (managed by David Jenkins) is the general partner.
• Exclusion of shares beneficially owned by certain adult immediate family members of Mr. Jenkins (23,532 shares).
• Exclusion of shares beneficially owned by the Jenkins Family Charitable Institute (676,360 shares), where Mr. Jenkins' adult daughter is the trustee.
• Exclusion of shares subject to outstanding warrants held by the Jenkins Family Charitable Institute (873,866 shares).
• Exclusion of Series X Preferred Stock held by Mr. Jenkins and his affiliates/associates (8171.57 shares convertible into 817,157 common shares).
• Exclusion of Series X Preferred Stock beneficially owned by certain adult immediate family members of Mr. Jenkins (1,067.715 shares convertible into 106,771 common shares).
• Exclusion of exercisable and unvested options held by Missiaen Huck (non-executive chief operating officer and Mr. Jenkins' adult daughter).
• Exclusion of Series J Warrants held by Casey A. Jenkins (Mr. Jenkins' adult daughter).

Stakeholder Impact

• Shareholders: The grant of stock options to the CEO aims to align management's interests with shareholder value. The updated beneficial ownership provides transparency regarding insider holdings. Potential future dilution from option exercise or conversion of other instruments is noted.
• Management: David Jenkins receives a significant incentive package, tying his future compensation to the company's stock performance.

Next Steps

• David Jenkins' stock options will continue to vest annually on January 29, 2026, 2027, and 2028.
• Reporting persons may make additional open market or other purchases or sales of Company common stock.
• Reporting persons may engage in estate planning or other transactions involving Company common stock.

Key Dates

Recommendation

Keywords

Catheter Precision, SEC Filing, Schedule 13D/A, Beneficial Ownership, Stock Options, David Jenkins, Executive Compensation, Corporate Governance, Medical Technology, Cardiac Electrophysiology, Investment Holding, Equity Incentive Plan